Peterlabs Holdings Bhd (XKLS:0171) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Peterlabs Holdings Bhd EBITDA Margin % Related Terms
Peterlabs Holdings Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0171 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a EBITDA Margin % of -5.24% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Peterlabs Holdings Bhd and its competitors. Over the past decade, Peterlabs Holdings Bhd's EBITDA Margin % has ranged from 1.11 to 9.61. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #711 out of 955 companies in the Drug Manufacturers industry, placing it in the top 74.5%.
Is Peterlabs Holdings Bhd's EBITDA Margin % too high?
Peterlabs Holdings Bhd's current EBITDA Margin % is -5.24%. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 9.61. Based on the distribution chart, Peterlabs Holdings Bhd ranks #711 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #711 out of 955 companies for EBITDA Margin %. This places Peterlabs Holdings Bhd in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Historically, Peterlabs Holdings Bhd's own EBITDA Margin % has ranged from 1.11 to 9.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current EBITDA Margin % is -5.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 17.5% above its estimated fair value. The current EBITDA Margin % is -5.24%. Peterlabs Holdings Bhd's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current EBITDA Margin % is -5.24% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued.
The current stock price of RM0.24 is trading 17.5% above its estimated GF Value™ of RM0.20.
GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0171:
EBITDA Margin %: -5.24%
GF Value™: RM0.20 vs. price of RM0.24 (17.5% above fair value)
No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
46GF Score
Get the complete analysis for XKLS:0171
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
